

Patrick Verschueren

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2557526/publications.pdf>

Version: 2024-02-01

152
papers

2,975
citations

159585

30
h-index

206112

48
g-index

154
all docs

154
docs citations

154
times ranked

3222
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Technical and Diagnostic Performance of 6 Assays for the Measurement of Citrullinated Protein/Peptide Antibodies in the Diagnosis of Rheumatoid Arthritis. <i>Clinical Chemistry</i> , 2007, 53, 498-504. | 3.2 | 147 |
| 2 | Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 305-317. | 13.7 | 145 |
| 3 | Treatment of early rheumatoid arthritis: A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. <i>Arthritis and Rheumatism</i> , 2007, 56, 3919-3927. | 6.7 | 122 |
| 4 | Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay. <i>Autoimmunity Reviews</i> , 2011, 10, 801-808. | 5.8 | 106 |
| 5 | Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 27-34. | 0.9 | 106 |
| 6 | Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. <i>Clinical Rheumatology</i> , 2007, 26, 1969-1971. | 2.2 | 96 |
| 7 | Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. <i>Rheumatology</i> , 2008, 47, 59-64. | 1.9 | 96 |
| 8 | Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 511-520. | 0.9 | 92 |
| 9 | Antinuclear antibody detection by automated multiplex immunoassay in untreated patients at the time of diagnosis. <i>Autoimmunity Reviews</i> , 2012, 12, 137-143. | 5.8 | 88 |
| 10 | Contemporary concepts of inflammation, damage and repair in rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2006, 20, 829-848. | 3.3 | 80 |
| 11 | Systemic Inflammation Affects Human Osteocyte-Specific Protein and Cytokine Expression. <i>Calcified Tissue International</i> , 2016, 98, 596-608. | 3.1 | 60 |
| 12 | CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2013-2016. | 0.9 | 56 |
| 13 | Detection of antinuclear antibodies by automated indirect immunofluorescence analysis. <i>Clinica Chimica Acta</i> , 2013, 415, 101-106. | 1.1 | 50 |
| 14 | Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the â€œJAK-potâ€™ collaboration. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1358-1366. | 0.9 | 48 |
| 15 | The presence of forefoot problems and the role of surgery in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1254-1255. | 0.9 | 46 |
| 16 | A detailed analysis of treatment delay from the onset of symptoms in early rheumatoid arthritis patients. <i>Scandinavian Journal of Rheumatology</i> , 2014, 43, 1-8. | 1.1 | 45 |
| 17 | Unraveling Patientâ€™Preferred Health and Treatment Outcomes in Early Rheumatoid Arthritis: A Longitudinal Qualitative Study. <i>Arthritis Care and Research</i> , 2016, 68, 1278-1287. | 3.4 | 45 |
| 18 | Predictors of remission, normalized physical function, and changes in the working situation during follow-up of patients with early rheumatoid arthritis: an observational study. <i>Scandinavian Journal of Rheumatology</i> , 2009, 38, 166-172. | 1.1 | 44 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 180-185. | 0.9 | 43 |
| 20 | Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA. <i>Rheumatology</i> , 2019, 58, 2284-2294. | 1.9 | 42 |
| 21 | CXCL8 and CCL20 Enhance Osteoclastogenesis via Modulation of Cytokine Production by Human Primary Osteoblasts. <i>PLoS ONE</i> , 2015, 10, e0131041. | 2.5 | 41 |
| 22 | Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2007, 26, 2205-2206. | 2.2 | 39 |
| 23 | The epidemiology of rheumatoid arthritis in Kinshasa, Democratic Republic of Congo—a population-based study. <i>Rheumatology</i> , 2012, 51, 1644-1647. | 1.9 | 39 |
| 24 | Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial. <i>Arthritis Research and Therapy</i> , 2015, 17, 97. | 3.5 | 38 |
| 25 | Performance characteristics of rheumatoid factor and anti-cyclic citrullinated peptide antibody assays may impact ACR/EULAR classification of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 667-677. | 0.9 | 38 |
| 26 | A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1069-1074. | 0.9 | 37 |
| 27 | Mechanical Loading Reduces Inflammation-Induced Human Osteocyte-to-Osteoclast Communication. <i>Calcified Tissue International</i> , 2015, 97, 169-178. | 3.1 | 36 |
| 28 | Benefit of anti-TNFalpha treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthritis complicated with amyloidosis and glomerulonephritis. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 368-369. | 0.9 | 33 |
| 29 | A new test set-up for skull fracture characterisation. <i>Journal of Biomechanics</i> , 2007, 40, 3389-3396. | 2.1 | 32 |
| 30 | Debilitating diarrhoea and weight loss due to colitis in two RA patients treated with leflunomide. <i>Clinical Rheumatology</i> , 2005, 24, 87-90. | 2.2 | 31 |
| 31 | Inflammatory factors in the circulation of patients with active rheumatoid arthritis stimulate osteoclastogenesis via endogenous cytokine production by osteoblasts. <i>Osteoporosis International</i> , 2014, 25, 2453-2463. | 3.1 | 31 |
| 32 | Likelihood ratios as a function of antibody concentration for anti-cyclic citrullinated peptide antibodies and rheumatoid factor. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 287-289. | 0.9 | 29 |
| 33 | Detection, identification and in vivo treatment responsiveness of bone morphogenetic protein (BMP)-activated cell populations in the synovium of patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 117-123. | 0.9 | 28 |
| 34 | Effectiveness of an integrated outpatient care programme compared with present-day standard care in early rheumatoid arthritis. <i>Musculoskeletal Care</i> , 2009, 7, 1-16. | 1.4 | 28 |
| 35 | One in five patients with rapidly and persistently controlled early rheumatoid arthritis report poor well-being after 1 year of treatment. <i>RMD Open</i> , 2020, 6, e001146. | 3.8 | 28 |
| 36 | The Association of Illness Perceptions with Physical and Mental Health in Systemic Sclerosis Patients: An Exploratory Study. <i>Musculoskeletal Care</i> , 2012, 10, 18-28. | 1.4 | 25 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study. <i>Clinical Rheumatology</i> , 2015, 34, 1687-1695. | 2.2 | 25 |
| 38 | Anti-PM/Scl-100 and anti-RNA-polymerase III antibodies in scleroderma. <i>Clinica Chimica Acta</i> , 2010, 411, 965-971. | 1.1 | 24 |
| 39 | Optimal care for early RA patients: the challenge of translating scientific data into clinical practice. <i>Rheumatology</i> , 2011, 50, 1194-1200. | 1.9 | 23 |
| 40 | Value-added reporting of antinuclear antibody testing by automated indirect immunofluorescence analysis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 547-51. | 2.3 | 22 |
| 41 | Are illness perception and coping style associated with the delay between symptom onset and the first general practitioner consultation in early rheumatoid arthritis management? An exploratory study within the CareRA trial. <i>Scandinavian Journal of Rheumatology</i> , 2016, 45, 171-178. | 1.1 | 22 |
| 42 | Orthopaedic surgery in patients with rheumatoid arthritis: a shift towards more frequent and earlier non-joint-sacrificing surgery. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 694-695. | 0.9 | 21 |
| 43 | Effectiveness of initial treatment allocation based on expert opinion for prevention of rapid radiographic progression in daily practice of an early RA cohort. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 634-637. | 0.9 | 20 |
| 44 | Patient-Reported Outcome Data From an Early Rheumatoid Arthritis Trial: Opportunities for Broadening the Scope of Treating to Target. <i>Arthritis Care and Research</i> , 2019, 71, 1566-1575. | 3.4 | 20 |
| 45 | Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 965-973. | 0.9 | 19 |
| 46 | Long-term efficacy of infliximab treatment for AA-amyloidosis secondary to chronic inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 759-761. | 0.9 | 18 |
| 47 | A general practice perspective on early rheumatoid arthritis management: A qualitative study from Flanders. <i>European Journal of General Practice</i> , 2015, 21, 231-237. | 2.0 | 18 |
| 48 | Physical therapy in adult inflammatory myopathy patients: a systematic review. <i>Clinical Rheumatology</i> , 2019, 38, 2039-2051. | 2.2 | 18 |
| 49 | The ideal mHealth-application for rheumatoid arthritis: qualitative findings from stakeholder focus groups. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 746. | 1.9 | 18 |
| 50 | Anti-TNF therapy and malignancy in spondyloarthritis in the Leuven spondyloarthritis biologics cohort (BIOSPAR). <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 71-6. | 0.8 | 18 |
| 51 | Heterogeneous nuclear RNPs as targets of autoantibodies in systemic rheumatic diseases. <i>Arthritis and Rheumatism</i> , 2012, 64, 213-221. | 6.7 | 17 |
| 52 | Two-year clinical and radiologic follow-up of early RA patients treated with initial step up monotherapy or initial step down therapy with glucocorticoids, followed by a tight control approach: lessons from a cohort study in daily practice. <i>Clinical Rheumatology</i> , 2014, 33, 125-130. | 2.2 | 17 |
| 53 | Factors influencing the prescription of intensive combination treatment strategies for early rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2014, 43, 265-272. | 1.1 | 17 |
| 54 | Patient experiences with intensive combination-treatment strategies with glucocorticoids for early rheumatoid arthritis. <i>Patient Education and Counseling</i> , 2015, 98, 384-390. | 2.2 | 17 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 556-565. | 0.9 | 17 |
| 56 | The performance of matrices in daily clinical practice to predict rapid radiologic progression in patients with early RA. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 627-631. | 3.4 | 16 |
| 57 | Treatment response and several patient-reported outcomes are early determinants of future self-efficacy in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2021, 23, 269. | 3.5 | 16 |
| 58 | Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open-Label Extension of a Randomized Clinical Trial. <i>ACR Open Rheumatology</i> , 2020, 2, 672-680. | 2.1 | 15 |
| 59 | Safety of immunomodulatory therapy in patients with bronchiectasis associated with rheumatic disease and IBD: a retrospective and cohort analysis. <i>Clinical Rheumatology</i> , 2012, 31, 367-373. | 2.2 | 14 |
| 60 | Does Including Pain, Fatigue, and Physical Function When Assessing Patients with Early Rheumatoid Arthritis Provide a Comprehensive Picture of Disease Burden?. <i>Journal of Rheumatology</i> , 2021, 48, 174-178. | 2.0 | 14 |
| 61 | Psychosocial Burden Predicts Sustained Remission in Early Rheumatoid Arthritis: Unraveling the Complex Interplay of Well-Being and Disease Activity. <i>Arthritis Care and Research</i> , 2023, 75, 758-767. | 3.4 | 14 |
| 62 | Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 937-943. | 0.9 | 14 |
| 63 | Heterogeneous Nuclear Ribonucleoprotein H1, a Novel Nuclear Autoantigen. <i>Clinical Chemistry</i> , 2009, 55, 946-954. | 3.2 | 13 |
| 64 | The optimal combination therapy for the treatment of early rheumatoid arthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1615-1625. | 1.8 | 13 |
| 65 | An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases. <i>Rheumatology</i> , 2020, 59, 1842-1852. | 1.9 | 13 |
| 66 | Short-term glucocorticoids reduce risk of chronic NSAID and analgesic use in early methotrexate-treated rheumatoid arthritis patients with favourable prognosis: subanalysis of the CareRA randomised controlled trial. <i>RMD Open</i> , 2021, 7, e001615. | 3.8 | 13 |
| 67 | Comorbidity burden in the first three years after diagnosis in patients with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis: a general practice registry-based study. <i>RMD Open</i> , 2021, 7, e001671. | 3.8 | 13 |
| 68 | A maximum difference scaling survey of barriers to intensive combination treatment strategies with glucocorticoids in early rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2015, 34, 861-869. | 2.2 | 12 |
| 69 | Illness representations of systemic lupus erythematosus and systemic sclerosis: a comparison of patients, their rheumatologists and their general practitioners. <i>Lupus Science and Medicine</i> , 2017, 4, e000232. | 2.7 | 12 |
| 70 | Multicentre study to improve clinical interpretation of rheumatoid factor and anti-citrullinated protein/peptide antibodies test results. <i>RMD Open</i> , 2022, 8, e002099. | 3.8 | 12 |
| 71 | Translating co-stimulation blockade into clinical practice. <i>Arthritis Research and Therapy</i> , 2008, 10, S4. | 3.5 | 11 |
| 72 | The perspective of patients with early rheumatoid arthritis on the journey from symptom onset until referral to a rheumatologist. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz035. | 0.7 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1423-1431. | 0.9 | 11 |
| 74 | Septic Arthritis Due to <i>Staphylococcus Warneri</i> : A Diagnostic Challenge. <i>Open Rheumatology Journal</i> , 2012, 6, 23-30. | 0.2 | 11 |
| 75 | Longitudinal trajectories of fatigue in early RA: the role of inflammation, perceived disease impact and early treatment response. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1385-1391. | 0.9 | 11 |
| 76 | Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1655-1659. | 0.9 | 10 |
| 77 | The phenotype and genotype of rheumatoid arthritis in the Democratic Republic of Congo. <i>Arthritis Research and Therapy</i> , 2013, 15, R89. | 3.5 | 10 |
| 78 | cDNA phage display for the discovery of theranostic autoantibodies in rheumatoid arthritis. <i>Immunologic Research</i> , 2017, 65, 307-325. | 2.9 | 10 |
| 79 | Prevalence and associated factors of subclinical atherosclerosis in rheumatoid arthritis at the university hospital of Kinshasa. <i>BMC Rheumatology</i> , 2019, 3, 37. | 1.6 | 10 |
| 80 | A systematic review on the effect of DMARDs on fertility in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 873-878. | 3.4 | 10 |
| 81 | OUP accepted manuscript. <i>Rheumatology</i> , 2021, 60, 3699-3708. | 1.9 | 10 |
| 82 | New indicator for discordance between patient-reported and traditional disease activity outcomes in patients with early rheumatoid arthritis. <i>Rheumatology</i> , 2022, 62, 108-115. | 1.9 | 9 |
| 83 | Psychological stress in rheumatoid arthritis: a systematic scoping review. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152014. | 3.4 | 9 |
| 84 | PAS-positive macrophagesâ€™ not always infection. <i>Lancet, The</i> , 2011, 377, 1890. | 13.7 | 8 |
| 85 | Assessment of Activity Limitations with the Health Assessment Questionnaire Predicts the Need for Support Measures in Patients with Rheumatoid Arthritis: A Multicenter Observational Study. <i>PLoS ONE</i> , 2014, 9, e106749. | 2.5 | 8 |
| 86 | From ELISA to Immunosorbent Tandem Mass Spectrometry Proteoform Analysis: The Example of CXCL8/Interleukin-8. <i>Frontiers in Immunology</i> , 2021, 12, 644725. | 4.8 | 8 |
| 87 | Tapering of Etanercept is feasible in patients with Rheumatoid Arthritis in sustained remission: a pragmatic randomized controlled trial. <i>Scandinavian Journal of Rheumatology</i> , 2022, 51, 470-480. | 1.1 | 8 |
| 88 | â€™More than just chitchatâ€™™: a qualitative study concerning the need and potential format of a peer mentor programme for patients with early rheumatoid arthritis. <i>RMD Open</i> , 2021, 7, e001795. | 3.8 | 8 |
| 89 | Increased cellularity and expression of adhesion molecules in muscle biopsy specimens from patients with rheumatoid arthritis with clinical suspicion of vasculitis, but negative routine histology. <i>Annals of the Rheumatic Diseases</i> , 2000, 59, 598-606. | 0.9 | 7 |
| 90 | Diagnostic characteristics of a gelatin based Waaler-Rose assay (Serodia-RA) for the detection of rheumatoid factor. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1169-1171. | 0.9 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | THU0137â€¦Associated with A Glucocorticoid Bridging Scheme, Methotrexate is as Effective Alone as in Combination with Other DMARDs for Early Rheumatoid Arthritis, with Fewer Reported Side Effects: 16 Weeks Remission Induction Data from the Carera Trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 226.2-226. | 0.9 | 7 |
| 92 | The use of glucocorticoids in early rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 1316-1317. | 1.9 | 7 |
| 93 | Rheumatoid granulomatous disease and pachymeningitis successfully treated with rituximab. <i>Acta Clinica Belgica</i> , 2018, 73, 307-312. | 1.2 | 7 |
| 94 | Proteoform Analysis of Matrix Metalloproteinase-9/Gelatinase B and Discovery of Its Citrullination in Rheumatoid Arthritis Synovial Fluids. <i>Frontiers in Immunology</i> , 2021, 12, 763832. | 4.8 | 7 |
| 95 | Anti-RuvBL1/2 autoantibodies in patients with systemic sclerosis or idiopathic inflammatory myopathy and a nuclear speckled pattern. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 742-744. | 0.9 | 7 |
| 96 | The efficacy and safety of abatacept in rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2010, 2, 89-94. | 2.7 | 6 |
| 97 | Treatment of rheumatoid arthritis with methotrexate in Congolese patients. <i>Clinical Rheumatology</i> , 2013, 32, 1323-1327. | 2.2 | 6 |
| 98 | Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 84-90. | 1.6 | 6 |
| 99 | Response to: â€œCorrespondence on â€œFive-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trialâ€™â€™ by Jain and Dhir<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e163-e163. | 0.9 | 6 |
| 100 | IgA rheumatoid factor in rheumatoid arthritis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 1617-1626. | 2.3 | 6 |
| 101 | Belgian rheumatologists' perception on eligibility of RA patients for anti-TNF treatment matches more closely Dutch rather than Belgian reimbursement criteria. <i>Rheumatology</i> , 2008, 48, 546-550. | 1.9 | 5 |
| 102 | THU0215â€¦Efficacy of sarilumab in patients with rheumatoid arthritis with and without previous response to tocilizumab. , 2018,, . | | 5 |
| 103 | The perception of stakeholders on the applicability of nurse-led clinics in the management of rheumatoid arthritis. <i>Rheumatology Advances in Practice</i> , 2021, 5, ii45-ii52. | 0.7 | 5 |
| 104 | Defining remission in patients with RA in clinical practice. <i>Nature Reviews Rheumatology</i> , 2012, 8, 445-447. | 8.0 | 4 |
| 105 | THU0121â€¦Comparison of MTX Therapy with or without A Moderate Dose Glucocorticoid Bridging Scheme in Early Rheumatoid Arthritis Patients Lacking Classical Poor Prognostic Markers: Week 16 Results from the Randomized Multicenter Carera Trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 220.1-220. | 0.9 | 4 |
| 106 | OP0137-HPRâ€¦Unravelling Preferred Outcomes of Disease and Treatment in Patients with Early Rheumatoid Arthritis: A Longitudinal Qualitative Interview Study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 112.2-112. | 0.9 | 3 |
| 107 | A mixed method study exploring patient satisfaction and feasibility of two exercise programmes in systemic sclerosis-associated microstomia. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab017. | 0.7 | 3 |
| 108 | Correspondence on â€œEULAR recommendations for a core data set for pregnancy registries in rheumatologyâ€™. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e44-e44. | 0.9 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Undifferentiated arthritis, not just another early manifestation of rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 3101-3103. | 1.9 | 3 |
| 110 | OP0180â€¦Remission Induction with Dmard Combinations and Glucocorticoids is not Superior to Remission Induction with MTX Monotherapy and Glucocorticoids: Week 52 Results of the High-Risk Group from the Carera Trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 139.2-139. | 0.9 | 2 |
| 111 | POS0503â€¦THE DISCORDANCE BETWEEN PATIENT-REPORTED AND CLINICAL/BIOLOGICAL OUTCOMES COULD HELP IN PREDICTING FUTURE DISEASE IMPACT IN PATIENTS WITH RHEUMATOID ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 484.1-484. | 0.9 | 2 |
| 112 | Does opioid-based pharmacotherapy have a place in rheumatoid arthritis therapy?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1-3. | 1.8 | 2 |
| 113 | Evaluation of Disease Burden by (Separate) Patient-reported, Clinical, and Laboratory Factor Scores in Patients With Established Rheumatoid Arthritis: A Factor Analysis Replication. <i>Journal of Rheumatology</i> , 2022, 49, 436-437. | 2.0 | 2 |
| 114 | Standardisation of ACPA tests: evaluation of a new candidate reference preparation. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1379-1384. | 0.9 | 2 |
| 115 | Non-infective endocarditis with systemic embolization and recurrent stroke in systemic sclerosis. <i>Rheumatology</i> , 2016, 55, kev381. | 1.9 | 1 |
| 116 | Separately tackling the development of erosions with denosumab: ultimately closing a gap in the treatment of patients with rheumatoid arthritis or trying too hard too late?. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 947-949. | 0.9 | 1 |
| 117 | Serum of patients with active rheumatoid arthritis inhibits differentiation of osteochondrogenic precursor cells. <i>Connective Tissue Research</i> , 2016, 57, 226-235. | 2.3 | 1 |
| 118 | 222â€¦Efficacy of sarilumab in patients with rheumatoid arthritis who previously received sarilumab or tocilizumab. <i>Rheumatology</i> , 2018, 57, . | 1.9 | 1 |
| 119 | SAT0214â€¦Effectiveness of a randomized step-down to methotrexate or leflunomide maintenance therapy in patients with low disease activity, 40 weeks after starting combined methotrexate-leflunomide remission induction therapy in early rheumatoid arthritis: results from the carera trial. , 2018, , . | | 1 |
| 120 | Primus inter pares: the choice of biologic drugs in rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 1325-1326. | 1.9 | 1 |
| 121 | SAT0135â€¦MAINTAINING REMISSION IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS WHILE TAPERING ETANERCEPT: AN INSIGHT IN THE TAPERA TRIAL. , 2019, , . | | 1 |
| 122 | Fulminant macrophage activation syndrome in a patient with anti-synthetase syndrome. <i>Rheumatology</i> , 2020, 59, 1775-1777. | 1.9 | 1 |
| 123 | O07â€¦Randomised, open labelled clinical trial to investigate synovial mechanisms determining response: resistance to rituximab versus tocilizumab in RA patients failing TNF inhibitor therapy. <i>Rheumatology</i> , 2020, 59, . | 1.9 | 1 |
| 124 | Effectiveness of maintenance therapy with methotrexate compared with leflunomide for patients with RA having achieved disease control with both these drugs: results of a predefined sub-analysis of CareRA, a pragmatic RCT. <i>Clinical Rheumatology</i> , 2020, 39, 2593-2601. | 2.2 | 1 |
| 125 | P440 First results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID). <i>Journal of Crohn's and Colitis</i> , 2021, 15, S440-S440. | 1.3 | 1 |
| 126 | SAT0028â€¦THE FLARE-RA QUESTIONNAIRE CAN PREDICT FLARES IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS PARTICIPATING IN THE TAPERA TRIAL. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 944.3-944. | 0.9 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | JAK inhibition and the holy grail for pain control in early RA. RMD Open, 2022, 8, e002068. | 3.8 | 1 |
| 128 | Antibodies to heterogeneous nuclear ribonucleoprotein H1 are directed to RNA recognition motif 3. Rheumatology, 2011, 50, 621-622. | 1.9 | 0 |
| 129 | Antibodies to hnRNPs in patients with a systemic rheumatic disease with no antibodies to extractable nuclear antigens or dsDNA. Rheumatology, 2012, 51, 1515-1516. | 1.9 | 0 |
| 130 | D veloppement d  une matrice de risque de la progression radiographique rapide   1 an apr  s diagnostic d  une polyarthrite rhumato  de d  butante. Revue Du Rhumatisme (Edition Francaise), 2016, 83, A249-A250. | 0.0 | 0 |
| 131 | Should rheumatoid arthritis patients preferentially be treated with tocilizumab after rituximab failure?. Rheumatology, 2016, 55, 197-198. | 1.9 | 0 |
| 132 | OP0226  ...Sustained effectiveness of methotrexate with step-down glucocorticoid remission induction (cobra slim) for early rheumatoid arthritis in a treat-to- target setting: 2-year results of the carera trial. , 2017, , . | | 0 |
| 133 | FRI0726  ...Long term use of analgesics and nsaid in early ra: lessons from the carera study. , 2017, , . | | 0 |
| 134 | Dysphagia during glucocorticoid treatment of dermatomyositis: a differential diagnostic challenge. Rheumatology Advances in Practice, 2018, 2, rky010. | 0.7 | 0 |
| 135 | THU0094  ...SERONEGATIVE RHEUMATOID ARTHRITIS: MILD NO MORE. , 2019, , . | | 0 |
| 136 | FRI0668  ...FIRST DATA OF THE TARDIS-RAREGISTRY, A NATIONWIDE BELGIAN BIOLOGIC REGISTRY. , 2019, , . | | 0 |
| 137 | THU0138  ...RHEUMATOLOGISTS     ADHERENCE TO THE TREAT-TO-TARGET PRINCIPLE IN EARLY RA PATIENTS WITHIN THE PRAGMATIC CARERA TRIAL: ROOM FOR IMPROVEMENT?. , 2019, , . | | 0 |
| 138 | P290 Compliance to vaccination guidelines in patients with immune-mediated inflammatory diseases: a cross-sectional, single-centre study. Journal of Crohn's and Colitis, 2019, 13, S244-S245. | 1.3 | 0 |
| 139 | Response to Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center. Seminars in Arthritis and Rheumatism, 2020, 50, e6. | 3.4 | 0 |
| 140 | Comment on: what is the best treatment for early rheumatoid arthritis?. Rheumatology, 2021, 60, e177-e178. | 1.9 | 0 |
| 141 | POS1434  ...WHICH PROGNOSTIC FACTORS MIGHT PREDICT THE NEED FOR TREATMENT ADAPTATION IN EARLY RHEUMATOID ARTHRITIS? A COMPARISON OF MACHINE LEARNING, SURVIVAL ANALYSIS AND REGRESSION METHODS. Annals of the Rheumatic Diseases, 2021, 80, 1001.2-1002. | 0.9 | 0 |
| 142 | Prescribing anti-rheumatic drugs in pregnancy and breastfeeding    the British Society for Rheumatology guideline scope. Rheumatology, 2022, 61, 480-481. | 1.9 | 0 |
| 143 | Belgian rheumatologists     preferences regarding measures of disease activity in patients with rheumatoid arthritis: results from a mixed-methods study. Rheumatology International, 2021, , 1. | 3.0 | 0 |
| 144 | AB0292  ...Autoantibodies to a novel peptide uh-ra.1 are associated with disease remission in rheumatoid arthritis. , 2018, , . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | FRI0640...Autoantibodies to two novel peptides in seronegative and early rheumatoid arthritis in three large independent cohorts. , 2018, , . | | 0 |
| 146 | OP0034...Long-term effectiveness of the cobra slim remission induction and treat to target strategy in patients with early rheumatoid arthritis lacking classical markers of poor prognosis: 2 year results of the carera trial. , 2018, , . | | 0 |
| 147 | FRI0596...NOVEL AUTOANTIBODY BIOMARKERS FOR THE PREDICTION OF THERAPY RESPONSE IN RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 904.1-904. | 0.9 | 0 |
| 148 | AB1209...A SYSTEMATIC REVIEW ON THE EFFECT OF DMARDS ON FERTILITY IN RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 1896.2-1896. | 0.9 | 0 |
| 149 | AB1153...ANALGESIC AND ANTI-INFLAMMATORY DRUG USE IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND SPONDYLOARTHRITIS VERSUS CONTROLS IN A BELGIAN GENERAL PRACTITIONER REGISTRY.. Annals of the Rheumatic Diseases, 2020, 79, 1867.1-1867. | 0.9 | 0 |
| 150 | P115 Implementation of a vaccination tool in the electronic patient health record significantly increases vaccination coverage. Journal of Crohn's and Colitis, 2022, 16, i206-i207. | 1.3 | 0 |
| 151 | P529 Evolution of COVID19 serology in a real-life population of IMID patients. Results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID). Journal of Crohn's and Colitis, 2022, 16, i482-i483. | 1.3 | 0 |
| 152 | Antistoffen tegen cyclisch gecitrullineerd peptide: een specifieke laboratoriumtest voor reumatoïde artritis. Tijdschrift Voor Geneeskunde, 2004, 60, 1167-1171. | 0.0 | 0 |